Table 1 Baseline data of the overall study cohort and with 1-y-FU (divided in patients with and without AF recurrence during 1-y-FU).
Patients’ baseline characteristics | |||||
|---|---|---|---|---|---|
All patients | AF recurrence | No AF recurrence | p-value | OR (95%-CI) | |
Number of patients | 3679 | 1687 (45.9%) | 1992 (54.1%) | ||
Male | 66.9% | 64.0% | 69.3% | <0.001 | 0.79 (0.69–0.90) |
Female | 33.1% | 36.0% | 30.7% | <0.001 | 1.27 (1.11–1.46) |
Age (MW) | 60.8 ± 10.1 | 61 ± 9.9 | 60.4 ± 10.7 | 0.23 | |
Comorbidities | |||||
Diabetes mellitus | 7.9% | 8.1% | 7.8% | 0.80 | 1.03 (0.81–1.31) |
Renal insufficiency* | 2.8% | 4.4% | 1.4% | 0.027 | 3.35 (1.08–10.41) |
Hypertension* | 61.5% | 62.4% | 60.7% | 0.67 | 1.07 (0.77–1.50) |
History of stroke* | 4.8% | 4.7% | 4.8% | 0.99 | 1.00 (0.47–2.13) |
CHD | 16.9% | 15.9% | 17.8% | 0.13 | 0.87 (0.74–1.04) |
History of myocardial infarction | 3.0% | 3.3% | 2.8% | 0.37 | 1.19 (0.81–1.73) |
Valvular disease | 8.2% | 9.2% | 7.3% | 0.035 | 1.29 (1.02–1.63) |
Cardiomyopathy (CM) | 3.4% | 3.6% | 3.3% | 0.69 | 1.08 (0.75–1.54) |
- Dilative CM | 73.1% | 70.0% | 75.8% | 0.47 | 0.75 (0.34–1.64) |
- Hypertrophic CM | 26.9% | 30.0% | 24.2% | 0.47 | 1.34 (0.61–2.95) |
LV-Function | |||||
LV-Fx: severely impaired (<=40%) | 5.0% | 4.7% | 5.3% | 0.53 | 0.84 (0.60–1.18) |
NYHA 2** | 34.4% | 40.0% | 29.6% | 0.011 | 1.58 (1.36–1.84) |
AF History | |||||
Paroxysmal (PAF) | 65.9% | 64.1% | 67.4% | 0.034 | 0.86 (0.75–0.99) |
Persistent (PersAF) | 26.6% | 26.9% | 26.4% | 0.75 | 1.02 (0.88–1.19) |
Long standing persistent | 7.5% | 9.0% | 6.2% | 0.001 | 1.51 (1.18–1.93) |
